Human ACP5 ELISA Kit (V2LY-0626-LY5783)

Name: Human ACP5 ELISA Kit
SKU: V2LY-0626-LY5783
Rating: 5 (1 reviews)

See all ACP5 antibodies

Compare Online Inquiry

Tested Data

Datasheet

SDS

Request for COA

Datasheet Target References Q & As Review & reward Protocols Associated Products

Basic Information

Sensitivity

0.23 U/L

Detection Range

0.5-20 U/L

Sample Type

Serum, Plasma, cell culture supernates

Specificity

Human

Assay Type

Sandwich

Reactivity

Human

Assay Time

1.5 h

Molecule Mass

36.6 kDa

Components

Pre-coated ELISA plate: 12 wells * 8 detachable strips
Standard solution: 0.5ml x1
Standard diluent: 3ml x1
Streptavidin-HRP: 6ml x1
Stop solution: 6ml x1
Substrate solution A: 6ml x1
Substrate solution B: 6ml x1
Wash buffer concentrate (25x): 20ml x1
Biotinylated antibody: 1ml x1

Formulations & Storage [For reference only, actual COA shall prevail!]

Storage

Store at 2-8°C

More Infomation

Target

Full Name

Acid Phosphatase 5, Tartrate Resistant

Function

Involved in osteopontin/bone sialoprotein dephosphorylation. Its expression seems to increase in certain pathological states such as Gaucher and Hodgkin diseases, the hairy cell, the B-cell, and the T-cell leukemias.

Biological Process

Bone resorption
Ossification
Riboflavin metabolic process

Cellular Location

Lysosome

Involvement in disease

Spondyloenchondrodysplasia with immune dysregulation (SPENCDI): A disease characterized by vertebral and metaphyseal dysplasia, spasticity with cerebral calcifications, and strong predisposition to autoimmune diseases. The skeletal dysplasia is characterized by radiolucent and irregular spondylar and metaphyseal lesions that represent islands of chondroid tissue within bone.

Shakya, M., Raizada, S., Yadav, R., & Singh, P. (2021). Computational Fine-Tuning of Functional Single Nucleotide Polymorphisms Associated with ACP5 Gene to Characterize Missense Mutations Running Title: SNP Analysis of ACP5 Gene.

Hu, Y., Yu, J., Wang, Q., Zhang, L., Chen, X., Cao, Y., ... & Xiong, W. (2020). Tartrate-resistant acid phosphatase 5/ACP5 interacts with p53 to control the expression of SMAD3 in lung adenocarcinoma. Molecular Therapy-Oncolytics, 16, 272-288.

Bai, X., He, C., Fu, B., Kong, X., Bu, J., Zhu, K., ... & Ni, B. (2020). microRNA-877 contributes to decreased non-small cell lung cancer cell growth via the PI3K/AKT pathway by targeting tartrate resistant acid phosphatase 5 activity. Cell Cycle, 19(23), 3260-3276.

Hu, Y., Yu, J., Wang, Q., Zhou, Q., Deng, Y., Liu, J., ... & Wang, Y. (2020). Tartrate-resistant acid phosphatase 5 serves as a viable target against pulmonary fibrosis by modulating β-catenin signaling.

Ramesh, J., Parthasarathy, L. K., Janckila, A. J., Begum, F., Murugan, R., Murthy, B. P., ... & Venugopal, B. (2020). Characterisation of ACP5 missense mutations encoding tartrate-resistant acid phosphatase associated with spondyloenchondrodysplasia. PloS one, 15(3), e0230052.

Huang, Y., Wang, L., Mao, Y., & Nan, G. (2019). Long noncoding RNA-H19 contributes to atherosclerosis and induces ischemic stroke via the upregulation of acid phosphatase 5. Frontiers in neurology, 10, 32.

He, C., Bai, X., Li, Y., Sun, H., Kong, X., Fu, B., ... & Xu, S. (2019). Runt-related transcription factor 1 contributes to lung cancer development by binding to tartrate-resistant acid phosphatase 5. Cell Cycle, 18(23), 3404-3419.

Reithmeier, A., Lundbäck, T., Haraldsson, M., Frank, M., Ek‐Rylander, B., Nyholm, P. G., ... & Andersson, G. (2018). Identification of inhibitors of Tartrate‐resistant acid phosphatase (TRAP/ACP 5) activity by small‐molecule screening. Chemical biology & drug design, 92(1), 1255-1271.

Gao, Y. L., Liu, M. R., Yang, S. X., Dong, Y. J., & Tan, X. F. (2018). Prognostic significance of ACP5 expression in patients with lung adenocarcinoma. The clinical respiratory journal, 12(3), 1100-1105.

Ren, X., Shan, W. H., Wei, L. L., Gong, C. C., & Pei, D. S. (2018). ACP5: Its structure, distribution, regulation and novel functions. Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry-Anti-Cancer Agents), 18(8), 1082-1090.

Ask a question We look forward to hearing from you.

0 reviews or Q&As

Purchasing FAQs
Technical FAQs

Have you used Human ACP5 ELISA Kit?
Submit a review and get a Coupon or an Amazon gift card. 20% off Coupon

$30 eGift Card
Submit a review

Please try the standard protocols which include: protocols, troubleshooting and guide.

Enzyme-linked Immunosorbent Assay (ELISA)
Flow Cytometry
Immunofluorescence (IF)
Immunohistochemistry (IHC)
Immunoprecipitation (IP)
Western Blot (WB)
Enzyme Linked Immunospot (ELISpot)
Proteogenomic
Other Protocols

Alternative Versions

Human Recombinant ACP5 protein, His Tag (CAT#: V2LY-0526-LY1904)

Mouse Recombinant ACP5 protein, His Tag (CAT#: V2LY-0526-LY7770)

Related Products

Mouse Anti-ACP5 Recombinant Antibody (V2-347940) (CAT#: CBMAB-T0012-YJ)

Human Recombinant ACP5 protein, His Tag (CAT#: V2LY-0526-LY1904)

Mouse Anti-ACP5 Recombinant Antibody (CBT2906) (CAT#: V2LY-0625-LY2859)

Mouse Anti-ACP5 Recombinant Antibody (V2-179379) (CAT#: CBMAB-A0681-YC)

Mouse Anti-ACP5 Recombinant Antibody (V2-179372) (CAT#: CBMAB-A0674-YC)

Mouse Anti-ACP5 Recombinant Antibody (V2-347936) (CAT#: CBMAB-T0007-YJ)

Mouse Anti-ACP5 Recombinant Antibody (V2-179376) (CAT#: CBMAB-A0678-YC)

Mouse Anti-ACP5 Recombinant Antibody (V2-179378) (CAT#: CBMAB-A0680-YC)

Mouse Anti-ACP5 Recombinant Antibody (CBT3149) (CAT#: V2LY-0625-LY68)

Mouse Recombinant ACP5 protein, His Tag (CAT#: V2LY-0526-LY7770)

Isotype control

For research use only. Not intended for any clinical use.

Custom Antibody Labeling

We also offer labeled antibodies developed using our catalog antibody products and nonfluorescent conjugates (HRP, AP, Biotin, etc.) or fluorescent conjugates (Alexa Fluor, FITC, TRITC, Rhodamine, Texas Red, R-PE, APC, Qdot Probes, Pacific Dyes, etc.).

Online Inquiry

Request bulk or custom quote Second antibody and isotype control

Contact us

Tel: (USA)
(UK)
Fax:

Global Locations

Email:

Online Inquiry